Company intelligence / Profile preview

4Tech

Ownership: Private
Development stage: Other

Overview

4Tech was a clinical-stage medical device company focused on developing minimally invasive solutions for the treatment of tricuspid regurgitation. The company's flagship product, the TriCinch System, was designed to repair the tricuspid valve through a transcatheter approach, avoiding the need for open-heart surgery. By cinching the tricuspid annulus, the device aimed to reduce valve diameter and restore competence. In 2020, the company was acquired by Edwards Lifesciences, a leader in structural heart disease and critical care monitoring. The acquisition integrated 4Tech's technology into Edwards' Transcatheter Mitral and Tricuspid Therapies (TMTT) portfolio, addressing a significant unmet need in cardiology.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on 4Tech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4Tech.

Explore the full profile